Skip to main content
. 2019 Dec 12;12:293. doi: 10.3389/fnmol.2019.00293

FIGURE 1.

FIGURE 1

Identification of candidate lncRNA markers in disseminated tumor cells (DTCs) in bone marrow and in stage 4 primary tumor. (A) Workflow for the identification of lncRNA in DTCs and primary tumor. On the left, six upregulated and three downregulated lncRNAs were identified in the DTC sample when compared to matched MNCs from bone marrow. On the right, eight lncRNAs were upregulated and no lncRNAs were significantly downregulated in primary tumor samples when compared to matched MNCs. (B) Significantly upregulated lncRNAs RFPL1S, PPP1R26-AS1, RP11-439E19.3, CASC15, AC004540.5, and CTD-2881E23.2 are commonly upregulated in both DTCs and primary tumor samples, while ZRANB2-AS2 and LINC00511 were two upregulated lncRNAs that are specific to DTCs. (C) CHRM3-AS3, USP3-AS1, and RP6-99M1.2 were significantly downregulated in tumor samples. (D) Venn diagram showing common and tumor-specific lncRNAs in the overall differential expression analysis. D/M represents DELs between DTCs and MNCs, while T/M represents DELs between primary tumor and MNCs. ∗p ≤ 0.05, ∗∗p ≤ 0.005, ∗∗∗p ≤ 0.0005, two-tailed unpaired t-test with Welch’s correction.